FDA recorded a supplement on 2 October 2026 to Mylan's abbreviated new drug application for generic clozapine (ANDA075417). The record does not state what the supplement changed. Supplements to generic applications usually cover manufacturing, labelling alignment or packaging rather than a new indication or a safety finding.
Nothing in this record changes how clozapine is prescribed or monitored. Blood monitoring, titration and the management of constipation, myocarditis and seizure risk follow the product labelling and local protocols as before. The Indian regulatory position for this specific product is not stated in the record.
- Make no change to clozapine prescribing or monitoring on the basis of this supplement.
- Check the current product labelling if a supplier change alters the brand your patient receives.
- Keep patients on the same manufacturer's product where possible, and recheck levels if it changes.
- Continue routine checks for constipation, which remains a common and dangerous adverse effect.
Why it matters
Regulatory records are worth reading carefully before assuming they carry clinical news.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free